🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hematological Malignancies
Clinical trial register · United States · industry-sponsored

Hematological Malignancies Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
New York 6 California 5 Alabama 3 Colorado 2 North Carolina 2
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC4 Miltenyi Biomedicine GmbH1 Lakefront Biotherapeutics NV1 AstraZeneca1 Smart Immune SAS1
State
New York6 California5 Alabama3 Colorado2 North Carolina2
All 17 states
Target enrolment
to
9 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
M-2018-334 in Hematological Malignancies
NCT06225050Hematological Malignancies
Miltenyi Biomedicine GmbH
Not applicable
18
California
2026-08-21
Recruiting
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
NCT07220616Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
Daiichi Sankyo
Phase 1/2
420
New York
2026-01-16
Recruiting
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
NCT06652633Hematological Malignancies
Lakefront Biotherapeutics NV
Phase 3
546
Massachusetts
2024-09-09
Recruiting
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
NCT04959903Hematological Malignancies
Smart Immune SAS
Phase 1/2
36
New York
2022-03-31
Recruiting
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552Hematological Malignancies
Janssen Research & Development, LLC
Phase 2
510
Alabama, Arkansas, California, Florida, Georgia, Illinois, Kentucky, Michigan
2021-02-01
Active, closed
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557098Hematological Malignancies
Janssen Research & Development, LLC
Phase 2
194
Alabama, California, Georgia, Michigan, New York, North Carolina, Pennsylvania
2020-09-17
Active, closed
Durvalumab and Tremelimumab for Pediatric Malignancies
NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
AstraZeneca
Phase 1/2
50
Maryland, Massachusetts, New York, Oklahoma, South Carolina
2019-03-07
Active, closed
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT03399799Hematological Malignancies
Janssen Research & Development, LLC
Phase 1
279
Alabama, California, Colorado, New York, Tennessee
2017-12-16
Active, closed
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
NCT03145181Hematological Malignancies
Janssen Research & Development, LLC
Phase 1
302
California, Colorado, New York, North Carolina, Pennsylvania
2017-05-16
Rows per page Showing 1–9 of 9
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/hematological-malignancies

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.